Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.

Alyssa A Toorop Zoé Léonie Elise van KempenMaurice SteenhuisJessica NielsenL G F SinnigeGert van DijkChristiaan M RoosendaalEdo P J ArnoldusElske HoitsmaBirgit I Lissenberg-WitteBrigit A de JongBob W van OostenEva M M StrijbisBernard M J UitdehaagTheo RispensJoep Killesteinnull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2023)

Natalizumab trough drug levels can decrease after switching from natalizumab intravenous to SC administration. We advise to monitor trough drug levels in patients with low natalizumab drug levels during intravenous treatment, patients with higher body mass index or patients on extended treatment intervals who switch to SC administration of natalizumab.

Keyphrases

multiple sclerosis
body mass index
high dose
end stage renal disease
newly diagnosed
chronic kidney disease
adverse drug
physical activity
prognostic factors
low dose
combination therapy
patient reported outcomes